(Q24185805)

English

Dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus (English)

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Bianca Hemmingsen

1

0 references

Jesper Krogh

2

0 references

Maria-Inti Metzendorf

3

0 references

Bernd Richter

4

0 references

publication date

19 May 2016

0 references

Cochrane Database of Systematic Reviews

0 references

Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Are systematic reviews up-to-date at the time of publication?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

The utility of fasting glucose for detection of prediabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

The incretin concept today

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Bias, precision and statistical power of analysis of covariance in the analysis of randomized trials with baseline imbalance: a simulation study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

A re-evaluation of random-effects meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Sequential methods for random-effects meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Clinical practice. Diagnosis of diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Industry sponsorship and research outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Comparison of registered and published primary outcomes in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

International Union of Pharmacology. XXXV. The glucagon receptor family

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Interpretation of random effects meta-analyses.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Racial differences in glycemic markers: a cross-sectional analysis of community-based data

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Predisease: When Does it Make Sense?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

The epidemic of pre-diabetes: the medicine and the politics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Designing psycho-oncology randomised trials and cluster randomised trials: variance components and intra-cluster correlation of commonly used psychosocial measures

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

21 January 2018

Dipeptidyl Peptidase-4 Inhibitor-Associated Pancreatic Carcinoma: A Review of the FAERS Database

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012204

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD012204

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24185805&oldid=1617929513"